Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S8 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
  1. Home
  2. Publications
  3. Supplementary Table S8 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma

Supplementary Table S8 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma

Authors:
  • EGElena Garralda
    Elena Garralda
  • CMChristoph Markert
    Christoph Markert
  • Victor Moreno
    Victor Moreno
  • ECEmiliano Calvo
    Emiliano Calvo
  • KRKristoffer Rohrberg
    Kristoffer Rohrberg
  • TKTae Min Kim
    Tae Min Kim
  • DLDae Ho Lee
    Dae Ho Lee
  • JCJonathan E. Cohen
    Jonathan E. Cohen
  • DLDarren W.T. Lim
    Darren W.T. Lim
  • FTFiona C. Thistlethwaite
    Fiona C. Thistlethwaite
  • BCByoung Chul Cho
    Byoung Chul Cho
  • YKYu Jung Kim
    Yu Jung Kim

Open Access
Publisher website
Google Scholar
  • 1 July 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.32845668
Abstract
Table S8. Response assessment per RECIST version 1.1.
Keywords
  • BIOMARKERS
  • CLINICAL TRIAL RESULTS
  • PHASE I CLINICAL TRIALS
  • SKIN CANCERS
  • MELANOMA
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.